Verteporfin Fluorescence in Antineoplastic-treated Pancreatic Cancer Cells Found Concentrated in Mitochondria

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2024 Apr 5

PMID 38577459

Authors

Ying-Qiao Zhang

Qing-Hao Liu

Lu Liu

Peng-Yu Guo

Run-Ze Wang

Zhi-Chang Ba

Affiliations

Soon will be listed here.

Abstract

Background: Traditional treatments for pancreatic cancer (PC) are inadequate. Photodynamic therapy (PDT) is non-invasive, and proven safe to kill cancer cells, including PC. However, the mitochondrial concentration of the photosensitizer, such as verteporfin, is key.

Aim: To investigate the distribution of fluorescence of verteporfin in PC cells treated with antitumor drugs, post-PDT.

Methods: Workable survival rates of PC cells (AsPC-1, BxPC-3) were determined with chemotherapy [doxorubicin (DOX) and gemcitabine (GEM)] and non-chemotherapy [sirolimus (SRL) and cetuximab (CTX)] drugs , with or without verteporfin, as measured MTT, flow cytometry, and laser confocal microscopy. Reduced cell proliferation was associated with GEM that was more enduring compared with DOX. Confocal laser microscopy allowed observation of GEM- and verteporfin-treated PC cells co-stained with 4',6-diamidino-2-phenylindole and MitoTracker Green to differentiate living and dead cells and subcellular localization of verteporfin, respectively.

Results: Cell survival significantly dropped upon exposure to either chemotherapy drug, but not to SRL or CTX. Both cell lines responded similarly to GEM. The intensity of fluorescence was associated with the concentration of verteporfin. Additional experiments using GEM showed that survival rates of the PC cells treated with 10 μmol/L verteporfin (but not less) were significantly lower relative to nil verteporfin. Living and dead stained cells treated with GEM were distinguishable. After GEM treatment, verteporfin was observed primarily in the mitochondria.

Conclusion: Verteporfin was observed in living cells. In GEM -treated human PC cells, verteporfin was particularly prevalent in the mitochondria. This study supports further study of PDT for the treatment of PC after neoadjuvant chemotherapy.

References

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Fargnoli M, Peris K . Photodynamic therapy for basal cell carcinoma. Future Oncol. 2015; 11(22):2991-6. DOI: 10.2217/fon.15.208. View

Celli J, Solban N, Liang A, Pereira S, Hasan T . Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med. 2011; 43(7):565-74. PMC: 3211106. DOI: 10.1002/lsm.21093. View

Yano T, Wang K . Photodynamic Therapy for Gastrointestinal Cancer. Photochem Photobiol. 2019; 96(3):517-523. DOI: 10.1111/php.13206. View

Lv W, Zhang Z, Yin Zhang K, Yang H, Liu S, Xu A . A Mitochondria-Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia. Angew Chem Int Ed Engl. 2016; 55(34):9947-51. DOI: 10.1002/anie.201604130. View

Wang Y, Wang H, Zhou L, Lu J, Jiang B, Liu C . Photodynamic therapy of pancreatic cancer: Where have we come from and where are we going?. Photodiagnosis Photodyn Ther. 2020; 31:101876. DOI: 10.1016/j.pdpdt.2020.101876. View

Kubrak T, Karakula M, Czop M, Kawczyk-Krupka A, Aebisher D . Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy. Molecules. 2022; 27(3). PMC: 8838614. DOI: 10.3390/molecules27030731. View

Gomez S, Tsung A, Hu Z . Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer. Molecules. 2020; 25(21). PMC: 7662882. DOI: 10.3390/molecules25214964. View

Pandit B, Royzen M . Recent Development of Prodrugs of Gemcitabine. Genes (Basel). 2022; 13(3). PMC: 8954202. DOI: 10.3390/genes13030466. View

10.

Taba F, Onoda A, Hasegawa U, Enoki T, Ooyama Y, Ohshita J . Mitochondria-Targeting Polyamine-Protoporphyrin Conjugates for Photodynamic Therapy. ChemMedChem. 2017; 13(1):15-19. DOI: 10.1002/cmdc.201700467. View

11.

Battaglia Parodi M, La Spina C, Berchicci L, Petruzzi G, Bandello F . Photosensitizers and Photodynamic Therapy: Verteporfin. Dev Ophthalmol. 2015; 55:330-6. DOI: 10.1159/000434704. View

12.

Saczko J, Mazurkiewicz M, Chwilkowska A, Kulbacka J, Kramer G, Lugowski M . Intracellular distribution of Photofrin in malignant and normal endothelial cell lines. Folia Biol (Praha). 2007; 53(1):7-12. View

13.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

14.

Sobhani N, Samadani A . Implications of photodynamic cancer therapy: an overview of PDT mechanisms basically and practically. J Egypt Natl Canc Inst. 2021; 33(1):34. DOI: 10.1186/s43046-021-00093-1. View

15.

Zhao H, Liu H, Kang L, Sun T, Liu Y, Chen D . In vitro and in vivo evaluation of a chlorin-based photosensitizer KAE® for cancer treatment. Photodiagnosis Photodyn Ther. 2022; 38:102759. DOI: 10.1016/j.pdpdt.2022.102759. View

16.

Huggett M, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M . Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014; 110(7):1698-704. PMC: 3974098. DOI: 10.1038/bjc.2014.95. View

17.

Ikeda N, Usuda J, Maehara S . Photodynamic therapy for central-type early-stage lung cancer. Gen Thorac Cardiovasc Surg. 2019; 68(7):679-683. DOI: 10.1007/s11748-019-01240-1. View

18.

Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V . Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2017; 111:152-165. DOI: 10.1016/j.critrevonc.2017.01.015. View

19.

Forster T, Huettner F, Springfeld C, Loehr M, Kalkum E, Hackbusch M . Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology. 2019; 98(1):53-60. DOI: 10.1159/000502844. View

20.

Tan Y, Zhang X, Zhang S, Zhu T, Garg M, Lobie P . Mitochondria: The metabolic switch of cellular oncogenic transformation. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188534. DOI: 10.1016/j.bbcan.2021.188534. View